Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial. (22nd April 2022)
- Record Type:
- Journal Article
- Title:
- Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial. (22nd April 2022)
- Main Title:
- Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial
- Authors:
- Torrens, Gabriel
van der Schalk, Thomas Ewout
Cortes-Lara, Sara
Timbermont, Leen
del Barrio-Tofiño, Ester
Xavier, Basil Britto
Zamorano, Laura
Lammens, Christine
Ali, Omar
Ruzin, Alexey
Goossens, Herman
Kumar-Singh, Samir
Kluytmans, Jan
Paling, Fleur
MacLean, R Craig
Köhler, Thilo
López-Causapé, Carla
Malhotra-Kumar, Surbhi
Oliver, Antonio - Abstract:
- Abstract: Objectives: To determine the susceptibility profiles and the resistome of Pseudomonas aeruginosa isolates from European ICUs during a prospective cohort study (ASPIRE-ICU). Methods: 723 isolates from respiratory samples or perianal swabs of 402 patients from 29 sites in 11 countries were studied. MICs of 12 antibiotics were determined by broth microdilution. Horizontally acquired β-lactamases were analysed through phenotypic and genetic assays. The first respiratory isolates from 105 patients providing such samples were analysed through WGS, including the analysis of the resistome and a previously defined genotypic resistance score. Spontaneous mutant frequencies and the genetic basis of hypermutation were assessed. Results: All agents except colistin showed resistance rates above 20%, including ceftolozane/tazobactam and ceftazidime/avibactam. 24.9% of the isolates were XDR, with a wide intercountry variation (0%–62.5%). 13.2% of the isolates were classified as DTR (difficult-to-treat resistance). 21.4% of the isolates produced ESBLs (mostly PER-1) or carbapenemases (mostly NDM-1, VIM-1/2 and GES-5). WGS showed that these determinants were linked to high-risk clones (particularly ST235 and ST654). WGS revealed a wide repertoire of mutation-driven resistance mechanisms, with multiple lineage-specific mutations. The most frequently mutated genes were gyrA, parC, oprD, mexZ, nalD and parS, but only two of the isolates were hypermutable. Finally, a good accuracy ofAbstract: Objectives: To determine the susceptibility profiles and the resistome of Pseudomonas aeruginosa isolates from European ICUs during a prospective cohort study (ASPIRE-ICU). Methods: 723 isolates from respiratory samples or perianal swabs of 402 patients from 29 sites in 11 countries were studied. MICs of 12 antibiotics were determined by broth microdilution. Horizontally acquired β-lactamases were analysed through phenotypic and genetic assays. The first respiratory isolates from 105 patients providing such samples were analysed through WGS, including the analysis of the resistome and a previously defined genotypic resistance score. Spontaneous mutant frequencies and the genetic basis of hypermutation were assessed. Results: All agents except colistin showed resistance rates above 20%, including ceftolozane/tazobactam and ceftazidime/avibactam. 24.9% of the isolates were XDR, with a wide intercountry variation (0%–62.5%). 13.2% of the isolates were classified as DTR (difficult-to-treat resistance). 21.4% of the isolates produced ESBLs (mostly PER-1) or carbapenemases (mostly NDM-1, VIM-1/2 and GES-5). WGS showed that these determinants were linked to high-risk clones (particularly ST235 and ST654). WGS revealed a wide repertoire of mutation-driven resistance mechanisms, with multiple lineage-specific mutations. The most frequently mutated genes were gyrA, parC, oprD, mexZ, nalD and parS, but only two of the isolates were hypermutable. Finally, a good accuracy of the genotypic score to predict susceptibility (91%–100%) and resistance (94%–100%) was documented. Conclusions: An overall high prevalence of resistance is documented European ICUs, but with a wide intercountry variability determined by the dissemination of XDR high-risk clones, arguing for the need to reinforce infection control measures. … (more)
- Is Part Of:
- Journal of antimicrobial chemotherapy. Volume 77:Number 7(2022)
- Journal:
- Journal of antimicrobial chemotherapy
- Issue:
- Volume 77:Number 7(2022)
- Issue Display:
- Volume 77, Issue 7 (2022)
- Year:
- 2022
- Volume:
- 77
- Issue:
- 7
- Issue Sort Value:
- 2022-0077-0007-0000
- Page Start:
- 1862
- Page End:
- 1872
- Publication Date:
- 2022-04-22
- Subjects:
- Anti-infective agents -- Periodicals
Chemotherapy -- Periodicals
615.58 - Journal URLs:
- http://jac.oxfordjournals.org ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/jac/dkac122 ↗
- Languages:
- English
- ISSNs:
- 0305-7453
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4939.100000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22265.xml